Confidence from Makers of Prostate Cancer Vaccine

Dendreon, the company that has spent millions of dollars developing a prostate cancer vaccine only to have its product, called Provenge, recently rejected by the FDA, is showing confidence that its re-application to the FDA will be accepted.

The company recently began offering stock in an effort to raise $15 million to build more manufacturing capacity for the vaccine and is already planning its commercial launch.

The FDA is expected to rule on the newest application next year.